PCVX vs. TEM: Vaxcyte vs. Tempus AI Stock Comparison

Company Profile

Vaxcyte (PCVX) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Vaxcyte (PCVX) is closer to market-like at 1.26 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Vaxcyte (PCVX) at -42.68% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Tempus AI (TEM) reports revenue growth of 83.41%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Neither Vaxcyte (PCVX) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Vaxcyte (PCVX) at 4.56 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Vaxcyte (PCVX) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Vaxcyte (PCVX) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Vaxcyte (PCVX) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither Vaxcyte (PCVX) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

A sales-based read is only available for Tempus AI (TEM), whose P/S ratio of 9.19 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics